CFDE Data Portal | Search ALDH1A3

	Label	Description
	ALDH1A3-AS1 Gene (Entity type)	ENSG00000259583 - ALDH1A3 antisense RNA 1
	GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE150244 TRIM8 knockout 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE144443 0 V 6 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

ALDH1A3-AS1

ENSG00000259583 - ALDH1A3 antisense RNA 1

GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN

A Gene Set from LINCS

GSE150244 TRIM8 knockout 3 v 0 human dn

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE199688 artemisinin 0 v 1 human dn

A Gene Set from LINCS

GSE144443 0 V 6 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

A Gene Set from LINCS

GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.